Search Within

Lee M Krug

  1. "Sloan Kettering Institute Postdocs"
Formats
  1. Journal Article (4)
  2. Meeting Abstract (4)
Groups
  1. Department of Medicine (8)
  2. GSK Faculty (8)
  3. Sloan Kettering Institute Postdocs (8)
  4. Tow Center for Developmental Oncology (TCDO) (8)
  5. Solid Tumor Oncology Division (7)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (6)

More Groups

People
  1. David Scheinberg (5)
  2. Marjorie Zauderer (5)
  3. Tao Dao (5)
  4. Valerie Rusch (4)
  5. Andreas Rimner (3)
  6. Marc Ladanyi (3)

More People

Years
  1. 2017 (1)
  2. 2016 (1)
  3. 2015 (2)
  4. 2012 (1)
  5. 2010 (2)
  6. 2008 (1)
Publications
  1. Journal of Clinical Oncology (3)
  2. Clinical Cancer Research (2)
  3. Blood (1)
  4. Cancer Immunology, Immunotherapy (1)
  5. Journal of Thoracic Oncology (1)
Publishers
  1. American Society of Clinical Oncology (3)
  2. American Association for Cancer Research (2)
  3. American Society of Hematology (1)
  4. Elsevier Inc. (1)
  5. Springer (1)

Results (8)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma
    Journal Article

    Zauderer, M. G.; Tsao, A. S.; Dao, T.; Panageas, K.; Lai, W. V.; Rimner, A.; Rusch, V. W.; Adusumilli, P. S.; Ginsberg, M. S.; Gomez, D.; more...
    Clinical Cancer Research (2017)

    Fulltext@MSK | Save
  • Randomized phase II study of adjuvant WT1 vaccine (SLS-001) for malignant pleural mesothelioma (MPM) after multimodality therapy
    Meeting Abstract

    Zauderer, M. G.; Dao, T.; Rusch, V. W.; Ginsberg, M. S.; Tsao, A. S.; Panageas, K.; Stergiou, A. M.; Scheinberg, D. A.; Krug, L. M.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • BAP1 inactivation in mesothelioma is highly prevalent
    Meeting Abstract

    Zauderer, M.; Cercek, A.; Rimner, A.; Rusch, V.; Adusumilli, P. S.; Nash, G. M.; Moreira, A.; Hmeljak, J.; Ladanyi, M.; Krug, L. M.
    Journal of Thoracic Oncology (2015)

    Fulltext@MSK | Save
  • Confirmation of high prevalence of BAP1 inactivation in mesothelioma
    Meeting Abstract

    Cercek, A.; Zauderer, M. G.; Rimner, A.; Rusch, V. W.; Adusumilli, P. S.; Nash, G. M.; Hmeljak, J.; Ladanyi, M.; Krug, L. M.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment
    Journal Article

    Ladanyi, M.; Zauderer, M. G.; Krug, L. M.; Ito, T.; McMillan, R.; Bott, M.; Giancotti, F.
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia
    Journal Article

    Maslak, P. G.; Dao, T.; Krug, L. M.; Chanel, S.; Korontsvit, T.; Zakhaleva, V.; Zhang, R.; Wolchok, J. D.; Yuan, J.; Pinilla-Ibarz, J.; more...
    Blood (2010)

    Fulltext@MSK | Save
  • WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
    Journal Article

    Krug, L. M.; Dao, T.; Brown, A. B.; Maslak, P.; Travis, W.; Bekele, S.; Korontsvit, T.; Zakhaleva, V.; Wolchok, J.; Yuan, J.; more...
    Cancer Immunology, Immunotherapy (2010)

    Fulltext@MSK | Save
  • Pilot trial of a Wilms tumor-1 (WT1) peptide vaccine in patients with thoracic and myeloid neoplasms
    Meeting Abstract

    Brown, A. B.; Krug, L. M.; Maslak, P.; James, L. P.; Dao, T.; Tyson, L.; Chanel, S. M.; Bekele, S.; Scheinberg, D. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save